MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

In the trial, the combination of Padcev with Merck & Co.'s Keytruda showed a clinically meaningful and statistically significant improvement in event-free survival and overall survival when used ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...